1, 4, 7, 10-tetraaza-2, 6-pyridine cyclophane and separation and detection method of intermediate of 1, 4, 7, 10-tetraaza-2, 6-pyridine cyclophane

The failure to monitor 1,4,7,10-tetraazea in the prior art is solved by step-by-step elution and reverse phase chromatography analysis using methanol, acetonitrile, DMSO mixed solution and octadecylsilane bonded silica gel columns. The problem of intermediate separation during the synthesis of -2,6-Pyridine ring-benzoic synthesis achieves controllability of product quality and monitoring of synthesis process.

CN119023836APending Publication Date: 2024-11-26JIANGSU BAODONG PHARM TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411117041.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-15
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The prior art cannot effectively monitor the separation of intermediates during the synthesis of 1,4,7,10-tetraazaz-2,6-pyridine ring-benzoic, making it difficult to control product quality.

Method used

Using mixed solutions of methanol, acetonitrile and DMSO as the analytical solution, combined with octadecylsilane-bonded silica gel chromatography column and phosphoric acid aqueous solution as the mobile phase, the detection of 1,4,7,10- Tetraazaz-2,6-pyridine ring and its intermediates realize the isolation detection and synthesis process monitoring of the intermediates.

Benefits of technology

Efficient separation and detection of 1,4,7,10-tetraazaz-2,6-pyridine ring and intermediate are achieved, ensuring the controllability of product quality and monitoring of synthesis process, and improving the quality of finished products.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119023836A_ABST
    Figure CN119023836A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of pharmaceutical analysis, in particular to 1, 4, 7, 10-tetraaza-2, 6-pyridine cyclophane and a separation and detection method of an intermediate of the 1, 4, 7, 10-tetraaza-2, 6-pyridine cyclophane. Preparing an analysis solution; wherein the analysis solution is formed by mixing one or more of methanol, acetonitrile and DMSO; preparing a chromatographic material which comprises a chromatographic column, a mobile phase A and a mobile phase B; wherein a chromatographic column is an octadecyl silane bonded silica gel chromatographic column, a mobile phase A is a phosphoric acid aqueous solution, and a mobile phase B is acetonitrile; eluting in a stepped manner; performing determination, injecting the analysis solution into a liquid chromatograph, performing chromatographic analysis, and recording a chromatogram; through the mode, separation detection can be carried out on each intermediate, and the synthesis process of 1, 4, 7, 10-tetraaza-2, 6-pyridine cyclophane is monitored, so that the quality of the product is controllable.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of drug analysis, and in particular to a 1,4,7,10-tetraaza-2,6-pyridine cyclophane and a separation and detection method for an intermediate thereof. Background Art

[0002] 1,4,7,10-tetraaza-2,6-pyridine cyclophane is a key material for the synthesis of a variety of nuclear magnetic resonance imaging developers and diagnostic reagents, and has very important application value. The structural formula of 1,4,7,10-tetraaza-2,6-pyridine cyclophane is as follows:

[0003]

[0004] 1,4,7,10-Tetraaza-2,6-pyridine cyclophane can be synthesized by the following synthetic method:

[0005]

[0006] The intermediates are: 2-nitro-N,N-bis(2-((2-nitrophenyl)sulfonamido)ethyl)benzenesulfonamide, 2,6-bis(chloromethylpyridine), and 3,6,9-tris((2-nitrophenyl)sulfonyl)-3,6,9-triaza-1(2,6)-pyridinecyclodecane.

[0007] In order to determine the yield of the synthetic product and indicate the reaction endpoint, the separation and detection of each intermediate is an important indicator for controlling the quality of the finished product. In the existing synthesis technology, it is impossible to separate and detect each intermediate.

[0008] In summary, it is very necessary to propose a method for separating and detecting each intermediate and monitoring the synthesis process of 1,4,7,10-tetraaza-2,6-pyridine cyclophane, so as to achieve a method for separating and detecting 1,4,7,10-tetraaza-2,6-pyridine cyclophane and its intermediates with controllable product quality. Summary of the invention

[0009] The object of the present invention is to provide a method for separating and detecting 1,4,7,10-tetraaza-2,6-pyridine cyclophane and its intermediates, which can separate and detect each intermediate and monitor the synthesis process of 1,4,7,10-tetraaza-2,6-pyridine cyclophane, thereby realizing a clear yield of the synthesis product and indicating the reaction endpoint.

[0010] To achieve the above object, the present invention adopts a method for separating and detecting 1,4,7,10-tetraaza-2,6-pyridine cyclophane and its intermediates, comprising the following steps:

[0011] Prepare an analytical solution; wherein the analytical solution is a mixture of one or more of methanol, acetonitrile, and DMSO;

[0012] Preparing chromatographic materials, including a chromatographic column, a mobile phase A and a mobile phase B; wherein the chromatographic column is an octadecylsilane bonded silica gel chromatographic column, the mobile phase A is a phosphoric acid aqueous solution, and the mobile phase B is acetonitrile;

[0013] Elution was performed in a stepwise manner;

[0014] Determination, injecting the analysis solution into a liquid chromatograph, performing chromatographic analysis, and recording a chromatogram.

[0015] Wherein, the chromatographic column is a reverse phase chromatographic column.

[0016] Wherein, the specifications of the chromatographic column are 4.6mm×150mm, 3.5μm.

[0017] Wherein, the concentration of the phosphoric acid aqueous solution is 0.08% to 0.12%.

[0018] Among them, in the step of eluting in a stepwise manner:

[0019] The time steps include 0-10min, 10-15min, 15-30min, 30-30.1min, 30.1-40min, and 40min;

[0020] During 0-10 min, the volume of mobile phase A is 90%, and the volume of mobile phase B is 10%;

[0021] At 10-15 min, the volume of mobile phase A is 90%, and the volume of mobile phase B is 10%;

[0022] At 15-30 min, the volume of the mobile phase A is 40%, and the volume of the mobile phase B is 60%;

[0023] At 30-30.1 min, the volume of the mobile phase A is 40%, and the volume of the mobile phase B is 60%;

[0024] 30.1-40min, the volume of the mobile phase A is 90%, and the volume of the mobile phase B is 10%;

[0025] At 40 minutes, the volume of the mobile phase A was 90%, and the volume of the mobile phase B was 10%.

[0026] Among them, in the step of eluting in a stepwise manner:

[0027] The elution flow rate is 0.8-1.2 ml / min; the elution column temperature is 25-35°C, and the detection wavelength is 210-230 nm.

[0028] The present invention discloses a method for separating and detecting 1,4,7,10-tetraaza-2,6-pyridine cyclophane and its intermediates, comprising preparing an analytical solution; wherein the analytical solution is a mixture of one or more of methanol, acetonitrile and DMSO; preparing chromatographic materials, including a chromatographic column, a mobile phase A and a mobile phase B; wherein the chromatographic column is an octadecylsilane bonded silica gel chromatographic column, the mobile phase A is a phosphoric acid aqueous solution, and the mobile phase B is acetonitrile; eluting is performed in a stepwise manner; and determining, injecting the analytical solution into a liquid chromatograph, performing chromatographic analysis, and recording the color spectrum; through the above method, it can be used for the detection of 1,4,7,10-tetraaza-2,6-pyridinecyclophane, 2-nitro-N,N-bis(2-((2-nitrophenyl)sulfonamido)ethyl)benzenesulfonamide, 2,6-bis(chloromethylpyridine) and 3,6,9-tris((2-nitrophenyl)sulfonyl)-3,6,9-triaza-1(2,6)-pyridinecyclodecane at the same time, and can separate and detect each intermediate, monitor the synthesis process of 1,4,7,10-tetraaza-2,6-pyridinecyclophane, so as to achieve product quality control. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0030] Figure 1 It is the detection chromatogram of Example 1 of the present invention.

[0031] Figure 2 It is the detection chromatogram of Example 2 of the present invention.

[0032] Figure 3 It is the detection chromatogram of Example 3 of the present invention.

[0033] Figure 4 It is the detection chromatogram of Example 4 of the present invention.

[0034] Figure 5 The invention discloses a flow chart of the steps of separating and detecting the 1,4,7,10-tetraaza-2,6-pyridine cyclophane and its intermediates. DETAILED DESCRIPTION

[0035] See also Figure 5 The present invention provides a method for separating and detecting 1,4,7,10-tetraaza-2,6-pyridine cyclophane and its intermediates, comprising the following steps:

[0036] S1: preparing an analytical solution; wherein the analytical solution is a mixture of one or more of methanol, acetonitrile and DMSO.

[0037] The analysis solution is a mixture of one or more of methanol, acetonitrile and DMSO, such as a single solvent of methanol, acetonitrile and DMSO, or a mixed solution of methanol-water, acetonitrile-water, methanol-acid and base to dissolve the sample.

[0038] S2: preparing chromatographic materials, including a chromatographic column, a mobile phase A and a mobile phase B; wherein the chromatographic column is an octadecylsilane bonded silica gel chromatographic column, the mobile phase A is a phosphoric acid aqueous solution, and the mobile phase B is acetonitrile.

[0039] The chromatographic column is an octadecylsilane bonded silica gel chromatographic column, the mobile phase A is a phosphoric acid aqueous solution, and the mobile phase B is acetonitrile; the chromatographic column is a reverse phase chromatographic column; the specifications of the chromatographic column are 4.6 mm×150 mm, 3.5 μm; the concentration of the phosphoric acid aqueous solution is 0.08% to 0.12%

[0040] S3: Elution was performed in a stepwise manner.

[0041] The elution was performed in a step-by-step manner, wherein the time steps included 0-10 min, 10-15 min, 15-30 min, 30-30.1 min, 30.1-40 min, and 40 min. The elution flow rate was 0.8-1.2 ml / min, the elution column temperature was 25-35° C., and the detection wavelength was 210-230 nm.

[0042] At 0-10 min, the volume of mobile phase A is 90%, and the volume of mobile phase B is 10%;

[0043] At 10-15 min, the volume of mobile phase A is 90%, and the volume of mobile phase B is 10%;

[0044] At 15 to 30 minutes, the volume of the mobile phase A is 40%, and the volume of the mobile phase B is 60%;

[0045] At 30-30.1 min, the volume of the mobile phase A is 40%, and the volume of the mobile phase B is 60%;

[0046] At 30.1-40 min, the volume of the mobile phase A is 90%, and the volume of the mobile phase B is 10%;

[0047] At 40 minutes, the volume of the mobile phase A was 90%, and the volume of the mobile phase B was 10%.

[0048] S4: Determination: injecting the analysis solution into a liquid chromatograph, performing chromatographic analysis, and recording a chromatogram.

[0049] In this embodiment, an analysis solution is prepared; wherein the analysis solution is a mixture of one or more of methanol, acetonitrile, and DMSO; a chromatographic material is prepared, including a chromatographic column, a mobile phase A, and a mobile phase B; wherein the chromatographic column is an octadecylsilane bonded silica gel chromatographic column, the mobile phase A is a phosphoric acid aqueous solution, and the mobile phase B is acetonitrile; elution is performed in a stepwise manner; and determination is performed by injecting the analysis solution into a liquid chromatograph, performing chromatographic analysis, and recording a chromatogram.

[0050] The structural formula of 1,4,7,10-tetraaza-2,6-pyridine cyclophane and its intermediates are shown in Table 1:

[0051]

[0052]

[0053] Table 1

[0054] The above method can be used for the detection of 1,4,7,10-tetraaza-2,6-pyridinecyclophane, 2-nitro-N,N-bis(2-((2-nitrophenyl)sulfonamido)ethyl)benzenesulfonamide, 2,6-bis(chloromethylpyridine) and 3,6,9-tris((2-nitrophenyl)sulfonyl)-3,6,9-triaza-1(2,6)-pyridinecyclodecane at the same time, and can separate and detect each intermediate, monitor the synthesis process of 1,4,7,10-tetraaza-2,6-pyridinecyclophane, so as to achieve product quality control.

[0055] Example 1

[0056] (1) Instruments and chromatographic conditions

[0057] High performance liquid chromatography: Agilent 1260II high performance liquid chromatography system and OPEN LAB CDS workstation;

[0058] Chromatographic column: Octadecylsilane bonded silica gel chromatographic column, this implementation uses Agilent Extend C18 (4.6 mm × 250 mm, 3.5 μm);

[0059] Prepare 0.1% phosphoric acid aqueous solution, mix it with methanol at a ratio of 70:30, and perform isocratic elution. Set the flow rate to 1.0 ml / min, the detection wavelength to 210 nm, and the column temperature to 30°C.

[0060] (2) Experimental procedures

[0061] Take appropriate amounts of 1,4,7,10-tetraaza-2,6-pyridinecyclophane, 2-nitro-N,N-bis(2-((2-nitrophenyl)sulfonamido)ethyl)benzenesulfonamide, 2,6-bis(chloromethylpyridine), and 3,6,9-tris((2-nitrophenyl)sulfonyl)-3,6,9-triaza-1(2,6)-pyridinecyclodecane, dissolve and dilute with 0.1% phosphoric acid aqueous solution-methanol (70:30) to prepare a solution containing about 1 mg of each in 1 ml as an analytical solution;

[0062] Take 10 μl of the above analysis solution and inject it into the liquid chromatograph to record the chromatogram. Figure 1 As shown, it can be seen that under this condition, the separation degree of 2-nitro-N,N-bis(2-((2-nitrophenyl)sulfonamido)ethyl)benzenesulfonamide, 2,6-bis(chloromethylpyridine), and 3,6,9-tris((2-nitrophenyl)sulfonyl)-3,6,9-triaza-1(2,6)-pyridinecyclodecane is average.

[0063] Example 2

[0064] (1) Instruments and chromatographic conditions

[0065] High performance liquid chromatography: Agilent 1260II high performance liquid chromatography system and OPEN LAB CDS workstation;

[0066] Chromatographic column: Waters Xbridge C18 (4.6 mm × 150 mm, 3.5 μm) octadecylsilane bonded silica gel chromatographic column;

[0067] Prepare 0.1% phosphoric acid aqueous solution as mobile phase A, and elute with acetonitrile according to the gradient shown in the table below, set the flow rate to 0.8ml / min, the detection wavelength to 220nm, and the column temperature to 25℃;

[0068] The above elution program is shown in Table 2:

[0069]

[0070] Table 2

[0071] (2) Experimental procedures

[0072] Take appropriate amounts of 2-nitro-N,N-bis(2-((2-nitrophenyl)sulfonamido)ethyl)benzenesulfonamide, 2,6-bis(chloromethylpyridine), and 3,6,9-tris((2-nitrophenyl)sulfonyl)-3,6,9-triaza-1(2,6)-pyridinecyclodecane, dissolve and dilute with DMSO-water (70:30) to prepare a solution containing about 1 mg of each per 1 ml as an analytical solution;

[0073] Take 10 μl of the above analysis solution and inject it into the liquid chromatograph to record the chromatogram. Figure 2 As shown, it can be seen that each intermediate can be completely separated, which is suitable for the purity control of each intermediate.

[0074] Example 3

[0075] (1) Instruments and chromatographic conditions

[0076] High performance liquid chromatography: Agilent 1260II high performance liquid chromatography system and OPEN LAB CDS workstation;

[0077] Chromatographic column: Waters Xbridge C18 (4.6 mm × 150 mm, 3.5 μm) octadecylsilane bonded silica gel chromatographic column;

[0078] Prepare 0.1% phosphoric acid aqueous solution as mobile phase A, and elute with acetonitrile according to the gradient shown in the table below. Set the flow rate to 1.0 ml / min, the detection wavelength to 220 nm, and the column temperature to 30°C;

[0079] The above elution procedure is shown in Table 3:

[0080]

[0081] Table 3

[0082] (2) Experimental procedures

[0083] Take appropriate amounts of 2-nitro-N,N-bis(2-((2-nitrophenyl)sulfonamido)ethyl)benzenesulfonamide, 2,6-bis(chloromethylpyridine), and 3,6,9-tris((2-nitrophenyl)sulfonyl)-3,6,9-triaza-1(2,6)-pyridinecyclodecane, dissolve and dilute with DMSO-water (70:30) to prepare a solution containing about 1 mg of each per 1 ml as an analytical solution;

[0084] Take 10 μl of the above analysis solution and inject it into the liquid chromatograph to record the chromatogram. Figure 3 As shown, it can be seen that each intermediate can be completely separated and the solvent peak is relatively large.

[0085] Example 4

[0086] (1) Instruments and chromatographic conditions

[0087] High performance liquid chromatography: Agilent 1260II high performance liquid chromatography system and OPEN LAB CDS workstation;

[0088] Chromatographic column: Waters Xbridge C18 (4.6 mm × 150 mm, 3.5 μm) octadecylsilane bonded silica gel chromatographic column;

[0089] Prepare 0.1% phosphoric acid aqueous solution as mobile phase A, and elute with acetonitrile according to the gradient shown in the table below. Set the flow rate to 1.0 ml / min, the detection wavelength to 220 nm, and the column temperature to 30°C;

[0090] The above elution procedure is shown in Table 4:

[0091] Time (min) Mobile phase A (%) Mobile phase B (%) 0 90 10 10 90 10 15 40 60 30 40 60 30.1 90 10 40 90 10

[0092] Table 4

[0093] (2) Experimental procedures

[0094] Take appropriate amounts of 1,4,7,10-tetraaza-2,6-pyridinecyclophane, 2-nitro-N,N-bis(2-((2-nitrophenyl)sulfonamido)ethyl)benzenesulfonamide, 2,6-bis(chloromethylpyridine), and 3,6,9-tris((2-nitrophenyl)sulfonyl)-3,6,9-triaza-1(2,6)-pyridinecyclodecane, dissolve them in water and dilute them to prepare a solution containing about 1 mg of each in 1 ml as the analytical solution;

[0095] Take 10 μl of the above analysis solution and inject it into the liquid chromatograph to record the chromatogram. Figure 4 As shown, it can be seen that the peak of 1,4,7,10-tetraaza-2,6-pyridine cyclophane is better.

[0096] What is disclosed above is only a preferred embodiment of the present invention, and it certainly cannot be used to limit the scope of rights of the present invention. Ordinary technicians in this field can understand that all or part of the processes of the above embodiment and equivalent changes made according to the claims of the present invention still fall within the scope of the invention.

Claims

1. A method for separating and detecting 1,4,7,10-tetraaza-2,6-pyridine cyclophane and its intermediates, characterized in that: The steps include: Prepare an analytical solution; wherein the analytical solution is a mixture of one or more of methanol, acetonitrile, and DMSO; Preparing chromatographic materials, including a chromatographic column, a mobile phase A and a mobile phase B; wherein the chromatographic column is an octadecylsilane bonded silica gel chromatographic column, the mobile phase A is a phosphoric acid aqueous solution, and the mobile phase B is acetonitrile; Elution was performed in a stepwise manner; Determination, injecting the analysis solution into a liquid chromatograph, performing chromatographic analysis, and recording a chromatogram.

2. The method for separating and detecting 1,4,7,10-tetraaza-2,6-pyridine cyclophane and its intermediates as claimed in claim 1, characterized in that: The chromatographic column is a reverse phase chromatographic column.

3. The 1,4,7,10-tetraaza-2,6-pyridine cyclophane and its intermediate separation and detection method as claimed in claim 1, characterized in that, The specifications of the chromatographic column are 4.6 mm×150 mm, 3.5 μm.

4. The 1,4,7,10-tetraaza-2,6-pyridine cyclophane and its intermediate separation and detection method as claimed in claim 1, characterized in that, The concentration of the phosphoric acid aqueous solution is 0.08% to 0.12%.

5. The 1,4,7,10-tetraaza-2,6-pyridine cyclophane and its intermediate separation and detection method as claimed in claim 1, characterized in that, In the step elution procedure: The time steps include 0-10min, 10-15min, 15-30min, 30-30.1min, 30.1-40min, and 40min; During 0-10 min, the volume of mobile phase A is 90%, and the volume of mobile phase B is 10%; At 10-15 min, the volume of mobile phase A is 90%, and the volume of mobile phase B is 10%; At 15-30 min, the volume of the mobile phase A is 40%, and the volume of the mobile phase B is 60%; At 30-30.1 min, the volume of the mobile phase A is 40%, and the volume of the mobile phase B is 60%; 30.1-40min, the volume of the mobile phase A is 90%, and the volume of the mobile phase B is 10%; At 40 minutes, the volume of the mobile phase A was 90%, and the volume of the mobile phase B was 10%.

6. The 1,4,7,10-tetraaza-2,6-pyridine cyclophane and its intermediate separation and detection method as claimed in claim 1, characterized in that, In the step elution procedure: The elution flow rate is 0.8-1.2 ml / min; the elution column temperature is 25-35°C, and the detection wavelength is 210-230 nm.